Milind Desai MD, FACC, FAHA, FESCHaslam Family Endowed Chair in CV Medicine and Professor of Medicine, CCLCM; Director, Clinical Operations. Director, HCM Center, Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio
Milind Desai, MD, is the Director of Clinical Operations of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine at the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute at Cleveland Clinic. He is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He holds the Haslam Family Endowed Chair in Cardiovascular Medicine. He has dual appointments in the Departments of Cardiovascular Medicine (Section of Cardiovascular Imaging) and Radiology.
Within the Heart and Vascular Institute, Dr. Desai is the Director of Center for Hypertrophic Cardiomyopathy, the Medical Director of the Center for Aortic Diseases, the Medical Director for Center for Radiation Heart Disease and an integral part of the Center for Valvular heart disease. He is an expert in multimodality cardiovascular imaging, having achieved the highest level of proficiency in all imaging modalities, including cardiac MRI, cardiac CT, echocardiography and nuclear cardiology.
Dr. Desai’s research interests include large outcomes studies in valvular heart disease, hypertrophic cardiomyopathy, radiation heart disease, coronary artery disease and aortic disorders. He is also an active researcher in noninvasive imaging using advanced echocardiography, CT and MRI; understanding the role of evolving techniques such as cardiac CT in cardiac risk prediction; stress testing in patients with valvular heart disease; outcomes assessment using multimodality imaging in ischemic and nonischemic cardiomyopathy, including hypertrophic cardiomyopathy. He is now active in leveraging use of Artificial Intelligence and imaging in predicting outcomes in various cardiac diseases.
Dr. Desai is the national PI of VALOR-HCM trial, sponsored by Myokardia, Inc. He has no financial conflicts of interest. He is on the steering committee of HCMR trial (NHLBI U01HL117006-01A1).